Rate My Professor Lloyd Einsiedel

Einsiedel's research focuses on viral infectious diseases, particularly Human T-Lymphotropic Virus type 1 (HTLV-1) subtype C, which is endemic among Aboriginal people in remote central Australian communities. His cross-sectional community surveys have revealed very high HTLV-1c prevalence rates, associations with bronchiectasis, pulmonary disease, bloodstream infections, diabetes, chronic kidney disease, and strongyloidiasis, as well as higher proviral loads linked to these conditions. Notable publications include 'Very high prevalence of infection with the human T cell leukaemia virus type 1c in remote Australian Aboriginal communities: Results of a large cross-sectional community survey' (2021), 'Pulmonary Disease Is Associated With Human T-Cell Leukemia Virus Type 1c Infection: A Cross-sectional Survey in Remote Aboriginal Communities' (2021), 'High level of genomic divergence in orf-I p12 and hbz genes of HTLV-1 subtype-C in Central Australia' (2024), 'Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo' (2025), and 'Bloodstream infection rates in Aboriginal and non-Aboriginal people in Central Australia, 2014-2018' (2023). With over 75 publications and more than 2,000 citations, his work has influenced public health. Einsiedel collaborated with the National Aboriginal Community Controlled Health Organisation HTLV-1 committee and Australian Department of Health to secure World Health Organization classification of HTLV-1 as a Threatening Pathogen to Humans in 2021, prompting international transmission reduction policies and Central Australian clinical guidelines.